News

If approved, roflumilast foam 0.3% for scalp and body psoriasis treatment would add to the multiple already-approved roflumilast indications.

As of July 19, 2024, there were 28 Listeria illnesses and 2 deaths linked to meats sliced at delis.

The Rare Pediatric Disease Designation from the FDA follows the previously granted Orphan Drug and Fast Track Designations.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Shreya Doshi, MBBS, FAAP, shares how routine screening appointments can serve as a good time to discuss environmental elements with families.

With no adverse events reported, findings suggested once-weekly PDL treatments are associated with improved outcomes and shorter treatment duration among children with effective PWB.

Shreya Doshi, MBBS, FAAP, discusses how contamination could be reducing your practice's recycling impact.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

When it comes to easing pain from a needlestick, pairing a dog with the human administering the needlestick was more successful than the human alone, according to results of a study conducted in a hematology oncology clinic.

A discussion on the importance of communication between healthcare providers, school personnel, families, and children in the administration and organization of medication in schools.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A cohort analysis shows state Medicaid programs could assure young children with sickle cell disease receive cost-efficient and critical care in a timely fashion.

A laboratory-based assessment shows children aged 18 - 32 months old were less likely to listen to attention prompts or their parent's requests when provided an iPad versus a standard toy.

Data from an Italy cohort show wheezing episodes decreased by more than 40% among children born during the COVID-19 lockdown period versus a pre-pandemic cohort.

Shreya Doshi, MBBS, FAAP, joined us to discuss some easy opportunities to reduce emissions in your practice and help improve health care sustainability.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

Details of newly FDA-approved roflumilast cream 0.15% for AD in pediatric patients, plus insight and commentary from Lawrence Eichenfield, MD.

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

The decision target action date was July 7, 2024. At this time, there is no indication from the federal agency to extend the date further.

Annie Certo, MA, and AJ Harris, MS, break down what a “summer slump” is and how it can affect children during summer break from school. The duo offers suggestions on how to combat the negative associations of a “summer slump.”

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

"Parents still ask about this. Indeed, many years ago the FDA approved a prescription form of a PUFA, Vayarin, for the treatment of patients with ADHD. It is no longer available, so I assume it did not work. There may be good reasons for taking a PUFA supplement, but having ADHD is not one of them." -Jon Matthew Farber, MD

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Matthew M. Davis, MD, MAAP, breaks down a newly-published study highlighting a potential association between COVID-19 vaccination and prevalence of symptomatic childhood asthma.

A discussion evaluating how social media can impact an individual's mental health, and what specific elements of social media could be causing it.

FDA decisions for the 2 accepted NDAs have target action dates of December 29 and December 30, 2024, respectively.

The submission to the FDA includes data from the phase 2b ReNeu trial of patients aged 2 years and older with NF1-associated PN causing significant morbidity.

"Obesity and treatment with growth hormone in children with PWS are known risk factors for hypoventilation as well as OSAS."- Jon Matthew Farber, MD